Author Correction: ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancer

EMBO Mol Med. 2024 Mar;16(3):664. doi: 10.1038/s44321-024-00029-x.

¹ Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
² Center for Advanced Preclinical Research, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
³ Merck KGaA, Biopharma R&D, Translational Innovation Platform Oncology, Frankfurter Street 250, 64293, Darmstadt, Germany.
⁴ Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
⁵ Medical Oncology Branch, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
⁶ EMD Serono Research and Development Institute Inc., Biopharma R&D, Translational Innovation Platform Oncology, Billerica, MA, 01821, USA.
⁷ Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA. anish.thomas@nih.gov.

Abstract